LEMAITRE VASCULAR INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LMAT in the last 30 days.
See all $LMAT insider activity →LeMaitre Vascular Inc. (LMAT) hit a 52-week low of $78.64, down 16.96% over the past year. The company reported Q2 earnings of $0.74 per share on $70.4M revenue, missing estimates. LMAT revised its full-year outlook downward but maintains strong fundamentals, with a PEG ratio of 0.71. InvestingPro suggests the stock is undervalued.
A specialty-stocks earnings recap compares Q2 results for LeMaitre (LMAT), Teleflex (TFX), Integra LifeSciences (IART), and Intuitive Surgical (ISRG). The group’s revenues beat consensus by 0.8%, but next-quarter guidance was 1.6% below. LMAT revenue was $70.38M (+9.6%) but missed by 1.7% and EPS. TFX revenue was $570.3M (+28.9%) beat by 2%. IART revenue $418.8M flat, in line. ISRG revenue $2.89B (+18.5%) beat by 2.6%.
LeMaitre Vascular (LMAT) reported Q2 2026 revenue of $70.4 million, up 10% organically, with diluted EPS of $0.74 (+23%). Gross margin rose to 72.1%. Artegraft sales grew 34% and now 21% of sales, while catheter sales fell 11%. Full-year guidance: revenue $274.3M-$278.3M, EPS $2.84-$2.94.
Over the past 7 days, alphai's AI scored 1 news story mentioning LMAT (LEMAITRE VASCULAR INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent LMAT coverage spans earnings, sector analysis and financial news.
Earnings disappointment may pressure the stock short-term.
Earnings and guidance disappointment around Artegraft launch and RFA setup appears to be the key near-term negative catalyst for LMAT.
Guidance and margin expansion, plus Artegraft growth, are likely to drive near-term sentiment, while cardiac allograft supply constraints and export delays are key offsets.
The article frames LMAT as fundamentally improving via Q2 results and guidance, but the stock’s recent underperformance raises valuation and execution questions.
The article frames a post-earnings selloff despite beat results, implying near-term positioning risk even with solid fundamentals.
alphai scores every news story that mentions LMAT with an AI model for sentiment and relevance, and aggregates insider trades from LEMAITRE VASCULAR INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
LeMaitre Vascular Inc. (LMAT) hit a 52-week low of $78.64, down 16.96% over the past year. The company reported Q2 earnings of $0.74 per share on $70.4M revenue, missing estimates. LMAT revised its full-year outlook downward but maintains strong fundamentals, with a PEG ratio of 0.71. InvestingPro suggests the stock is undervalued.
1 min readA specialty-stocks earnings recap compares Q2 results for LeMaitre (LMAT), Teleflex (TFX), Integra LifeSciences (IART), and Intuitive Surgical (ISRG). The group’s revenues beat consensus by 0.8%, but next-quarter guidance was 1.6% below. LMAT revenue was $70.38M (+9.6%) but missed by 1.7% and EPS. TFX revenue was $570.3M (+28.9%) beat by 2%. IART revenue $418.8M flat, in line. ISRG revenue $2.89B (+18.5%) beat by 2.6%.
7 min readLeMaitre Vascular (LMAT) reported Q2 2026 revenue of $70.4 million, up 10% organically, with diluted EPS of $0.74 (+23%). Gross margin rose to 72.1%. Artegraft sales grew 34% and now 21% of sales, while catheter sales fell 11%. Full-year guidance: revenue $274.3M-$278.3M, EPS $2.84-$2.94.
6 min readSimply Wall St reports LeMaitre Vascular (LMAT) released Q2 2026 results with higher sales and net income, updated guidance, and a reaffirmed cash dividend. It notes the stock’s recent 7-day and 30-day returns of about 21% and 21% versus 3- and 5-year TSR near 48% and 52%. It cites a fair value of $118.75 versus a last close of $81.45 and a P/E of 28.4x.
6 min readConestoga Capital Advisors’ Q2 2026 investor letter discussed LeMaitre Vascular (NASDAQ:LMAT), citing 10% organic revenue growth, 72.1% gross margins, and adjusted EPS of $0.68 versus $0.66 consensus. Despite strong fundamentals, LMAT shares fell after earnings as investors took profits. LMAT closed Aug. 5 at $79, with a $1.81B market cap.
4 min readA market movers roundup highlights five stocks. LeMaitre (LMAT) fell 18.6% after Q2 results missed expectations and forecast was weak. ePlus (PLUS) dropped 5.1% despite Q2 2026 beating estimates. Booking (BKNG) rose 6.6% on Q2 results above estimates. Paymentus (PAY) fell 9.2% on cautious Q2 narrative. Vishay Intertechnology (VSH) slid 8.8% after mixed Q2 results, with revenue missing.
2 min readLeMaitre Vascular (NASDAQ: LMAT) shares fell 18.6% after Q2 results missed expectations and guidance weakened. Revenue was $70.38M vs $71.61M consensus, EPS was $0.74 vs $0.81. Q3 revenue guidance was $67.3M, about 3% below estimates, and full-year revenue was cut to $276.3M from $280M.
4 min readLeMaitre Vascular (NASDAQ:LMAT) reported Q2 CY2026 revenue of $70.38 million, up 9.6% year on year but below Wall Street estimates. Next-quarter revenue guidance was $67.3 million, about 3% under analysts’ expectations. GAAP EPS was $0.74, 8.3% below consensus. The stock fell 11.6% to $93.53 after results.
4 min readLEMAITRE VASCULAR INC (LMAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LeMaitre Q2 2026 Financial Results BURLINGTON, MA, August 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance. Q
6 min readLeMaitre Vascular (NASDAQ: LMAT) will report earnings Tuesday after market close. The prior quarter revenue was $66.55 million, up 11.2% year over year, and it met revenue expectations. For the upcoming quarter, analysts expect revenue growth of 11.5% y/y. The average analyst price target is $118.75 versus $101.32.
4 min read
